Archives

PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in Combination With Ipilimumab

Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, Patricia LoRusso, Manreet Randhawa, Ferry Albert Louis Maria Eskens, Rachel E. Sanborn, Nataliya Uboha, Daniel Cho, Alexander I. Spira, Igor Bondarenko, Ruth Plummer, Javier Garcia-Corbacho, Ivan Victoria, Javier Lavernia, Ignacio Melero, E.G.E. DeVries, Will Garner, Hendrik-Tobias Arkenau, Johanna Bendell. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Evidence of Intratumoral Localization, Activation, and Immunomodulatory Effect of CX-072, a PROBODY Therapeutic Targeting PD-L1, in a Phase 1/2 Trial

Susan K. Lyman, Aung Naing, Ivan A. Zein, Yuanbin Ru, Bruce Howng, Michael B. Winter, Olga Vasiljeva, Will Garner, Beiyao Zheng, Mark Stroh, Hong Lu, Jennifer Richardson, W. Michael Kavanaugh, Luc R. Desnoyers. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

Preliminary Population Pharmacokinetics Supports Phase 2 Dose Selection for Masked Anti–PD-L1 Antibody CX-072

Mark Stroh, Michelle Green, B.L. Millard, Will Garner, Hong Lu, Jennifer Richardson, Lawrence Lu, Alison Hannah. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Learn More

CX-072, a PD-L1 Probody Therapeutic, as Monotherapy in Patients With Advanced Solid Tumors: Preliminary Results of PROCLAIM-CX-072

Aung Naing, Fiona Thistlethwaite, Alexander Spira, Javier Garcia-Corbacho, Manreet Randhawa, Ferry ALM Eskens, Greg Durm, Nataliya Uboha, Omid Hamid, Anthony El-Khoueiry, Vanessa Huels, Will Garner, Beverly Benson, Hendrik-Tobias Arkenau, Patricia LoRusso. Poster presented at ASCO 2019, May 31-June 4, Chicago, Illinois.

Learn More

PROCLAIM-CX-072: Monotherapy for Advanced Triple-Negative Breast Cancer With Skin Metastases in a Phase 1/2a Trial of the PD-L1 Probody Therapeutic CX-072

Sylvia Adams, Erika Hamilton, Patrick A. Ott, Daniel Cho, Kevin Kalinsky, Patricia LoRusso, Matthias Will, Vanessa Huels, Beverly Benson, Carmen Murias, Hendrik-Tobias Arkenau. Poster presented at the 41st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas.

Learn More

Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2 Trial

Susan K. Lyman, Judi Gordon, Amy DuPage, Preeti Pramanik, Bruce Howng, Ivan A. Zein, Michael B. Winter, Irina K. Popova, Olga Vasiljeva, James Jones, Ken Wong, Victoria Singson, Jennifer Richardson, Beiyao Zheng, Mark Stroh, Lori Carman, Vanessa Huels, Karen Autio, Valentina Boni, Daniel Cho, Javier Garcia-Corbacho, Iván Victoria Ruiz, Omid Hamid, Nataliya Uboha, Elisabeth de Vries, Anthony El-Khoueiry, Alexander Spira, Rachel E. Sanborn, Fiona Thistlethwaite, Hendrik-Tobias Arkenau, Johanna Bendell, Patrick A. Ott, Naiyer Rizvi, Matthias Will, W. Michael Kavanaugh, Aung Naing, Luc R. Desnoyers. Poster presented at SITC 2018, November 7-11, Washington, D.C.

Learn More

Preliminary Results of PROCLAIM-CX-072: The First-in-Human, Dose-Finding Trial of PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients With Advanced Solid Tumors

Valentina Boni, Javier Garcia-Corbacho, Patrick A. Ott, Daniel Cho, Karen A. Autio, Nataliya Uboha, Alexander I. Spira, Rachel Humphrey, Matthias Will, Aung Naing, Fiona Thistlethwaite, Elisabeth de Vries, Hendrik-Tobias Arkenau. Poster presented at ESMO 2018, October 19-23, Munich, Germany.

Learn More

Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial Evaluating the PD-L1 Probody Therapeutic CX-072 in Combination With Ipilimumab in Patients With Advanced Solid Tumors

Ruth Plummer, Rachel E. Sanborn, Elisabeth de Vries, Patricia LoRusso,Hendrik-Tobias Arkenau, Nataliya Uboha, Jerzy Wydmanski, Mary Josephine Fidler, Valentina Boni, Javier Garcia-Corbacho, Rachel Humphrey, Matthias Will, Karen A. Autio, Anthony El-Khoueiry, C. Willemien Menke-van der Houven van Oordt, Fiona Thistlethwaite. Poster presented at ESMO 2018, October 19-23, Munich, Germany.

Learn More

Preliminary Interim Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic (Pb-Tx) CX-072 in Combination with Ipilimumab (ipi) in Patients (pts) with Advanced Solid Tumors

Rachel E. Sanborn, Catharina Wilhelmina Menke, Karen A. Autio, Hendrik-Tobias Arkenau, Javier Garcia Corbacho, Patricia LoRusso, Elizabeth Ruth Plummer, Nataliya Volodymyrivna Uboha, Morganna Louise Freeman, Jerzy Wydmanski, Vanessa Huels, Beiyao Zheng, Matthias Will, Rachel W. Humphrey, Fiona Thistlethwaite, Elisabeth G.E. de Vries, Anthony B. El-Khoueiry. Poster presented at ASCO 2018, June 1-5, Chicago, Illinois.

Learn More

Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients (pts) with Advanced Solid Tumors

Karen A. Autio, Hendrik-Tobias Arkenau, Bert H. O’Neil, Johanna C. Bendell, Anthony El-Khoueiry, James Strauss, Amy Weise, Nataliya Volodymyrivna Uboha, Naiyer A. Rizvi, Beiyao Zheng, Luc Desnoyers, Mark Stroh, Lori Carman, Rachel W. Humphrey, Matthias Will, Valentina Boni, Alexander I. Spira, Aung Naing. Poster presented at ASCO 2018, June 1-5, Chicago, Illinois.

Learn More